TargetMol

Crenigacestat

Product Code:
 
TAR-T3633
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3633-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3633-1mg1mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3633-5mg5mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3633-1mL1 mL * 10 mM (in DMSO)£169.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3633-10mg10mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3633-25mg25mg£369.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
LY3039478 is an orally bioavailable Notch inhibitor with an IC50 of ~1 nM in most of the tumor cell lines tested. LY3039478 effectively inhibits mutant Notch receptor activity. In a xenograft tumor model, LY3039478 inhibited expression of Notch-regulated genes and N1ICD cleavage in the tumor microenvironment.
CAS:
1421438-81-4
Formula:
C22H23F3N4O4
Molecular Weight:
464.445
Pathway:
Neuroscience; Stem Cells; Proteases/Proteasome
Purity:
0.9876
SMILES:
C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2cccnc2N(CCO)C1=O
Target:
Gamma-secretase

References

M?emets-Allas K, et al. Biochem Biophys Res Commun. 2016 May 20;474(1):118-25. Lu B, He Y, He J, et al. Epigenetic profiling identifies LIF as a super-enhancer controlled regulator of stem cell-like properties in osteosarcoma. Molecular Cancer Research. 2020, 18(1): 57-67 Lu B, He Y, He J, et al. Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell?like Properties in Osteosarcoma[J]. Molecular Cancer Research. 2020, 18(1): 57-67. Bhagat TD, et al. J Biol Chem. 2017, 292(3):837-846. Eli Lilly Company. The 8th SCI-RSC Symposium on Proteinase Inhibitor Design. 2013. Mark H. Bender, et al. Cancer Res, 2013, 73(8 Suppl):Abstract nr 1131.